MDT

Medtronic
D

MDT

Arincen70/100B

Medtronic cash flow statement 1990–2027

Medtronic's free cash flow over the last twelve months was 6.13B USD: operating cash flow of 8.04B USD less 1.90B USD of capital spending. That is 16.3% of its revenue and 4.76 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
31 Jul 2026
FY2026
24 Apr 2026
FY2025
25 Apr 2025
FY2024
26 Apr 2024
FY2023
28 Apr 2023
FY2022
29 Apr 2022
FY2021
30 Apr 2021
FY2020
30 Apr 2020
FY2019
26 Apr 2019
FY2018
27 Apr 2018
FY2017
28 Apr 2017
Net income
5.27B4.84B4.69B3.68B3.78B5.06B3.63B4.81B4.65B3.10B4.02B
Depreciation and amortization
2.85B2.96B2.86B2.65B2.70B2.71B2.70B2.66B2.66B2.64B2.92B
Stock-based compensation
496.00M457.00M429.00M393.00M355.00M359.00M344.00M297.00M290.00M344.00M348.00M
Change in working capital
-941.00M-1.42B-1.05B-484.00M-967.00M-889.00M-701.00M61.00M-1.08B-173.00M139.00M
Change in receivables
-264.00M-200.00M-433.00M-391.00M-576.00M-477.00M-761.00M1.29B-581.00M-275.00M-75.00M
Change in inventory
-271.00M-404.00M-292.00M-139.00M-939.00M-560.00M78.00M-577.00M-274.00M-192.00M-227.00M
Change in payables
113.00M46.00M209.00M391.00M696.00M213.00M531.00M-44.00M399.00M65.00M356.00M
Change in other working capital
-519.00M-865.00M-538.00M-345.00M-148.00M-65.00M-549.00M-609.00M-624.00M229.00M85.00M
Other non-cash items
352.00M450.00M433.00M1.06B396.00M711.00M687.00M722.00M792.00M-307.00M-89.00M
Operating cash flow
8.04B7.33B7.04B6.79B6.04B7.35B6.24B7.23B7.01B4.68B6.88B
Operating cash flow growth
+12.44%+4.06%+3.79%+12.39%-17.79%+17.72%-13.74%+3.24%+49.59%-31.92%+31.85%
Capital expenditure
-1.90B-1.90B-1.86B-1.59B-1.46B-1.37B-1.36B-1.21B-1.13B-1.07B-1.25B
Acquisitions
—-406.00M-98.00M-211.00M-1.87B-91.00M-994.00M-488.00M-1.83B5.92B-1.32B
Purchases of investments
-8.82B-8.73B-8.23B-7.75B-7.51B-9.88B-11.81B-11.04B-2.53B-3.20B-4.37B
Sales and maturities of investments
8.30B8.11B8.50B7.44B7.34B9.69B11.35B9.57B4.68B4.23B5.36B
Other investing
148.00M-4.00M-249.00M-261.00M4.00M-10.00M-54.00M-37.00M36.00M-22.00M22.00M
Investing cash flow
-3.83B-2.93B-1.94B-2.37B-3.49B-1.66B-2.87B-3.20B-774.00M5.86B-1.57B
Debt issued (repaid)
151.00M-1.17B2.14B1.07B-598.00M-1.00M-570.00M-559.00M-867.00M-7.60B2.18B
Shares issued
441.00M516.00M508.00M284.00M308.00M429.00M474.00M662.00M992.00M403.00M428.00M
Share buybacks
-1.18B-1.04B-3.24B-2.14B-645.00M-2.54B-652.00M-1.33B-2.88B-2.17B-3.54B
Dividends paid
-3.65B-3.64B-3.59B-3.67B-3.62B-3.38B-3.12B-2.89B-2.69B-2.49B-2.38B
Other financing
525.00M582.00M-184.00M-3.00M-101.00M163.00M206.00M581.00M14.00M-94.00M26.00M
Financing cash flow
-3.71B-4.75B-4.36B-4.45B-4.96B-5.34B-4.14B-4.20B-5.43B-11.95B-3.28B
Net change in cash
418.00M-269.00M934.00M-259.00M-2.17B121.00M-547.00M-253.00M724.00M-1.30B2.09B
Free cash flow
6.13B5.43B5.19B5.20B4.58B5.98B4.89B6.02B5.87B3.62B5.63B
Free cash flow growth
+15.63%+4.65%-0.29%+13.54%-23.39%+22.37%-18.87%+2.52%+62.42%-35.73%+34.85%
Free cash flow margin
16.33%14.92%15.46%16.07%14.67%18.87%16.22%20.82%19.22%12.07%18.94%
Free cash flow per share
4.764.214.023.913.444.423.614.464.332.644.04
Free cash flow per share growth
+15.61%+4.79%+2.83%+13.76%-22.32%+22.61%-19.04%+3.01%+63.70%-34.64%+38.20%
Interest paid
776.00M774.00M762.00M826.00M606.00M540.00M582.00M643.00M973.00M1.15B1.13B
Income taxes paid
—1.94B1.82B1.62B1.55B996.00M1.25B878.00M1.56B2.54B1.03B

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Medtronic's cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.